{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"2.590","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"499,809,788","primaryexch":"香港交易所","ric":"1228.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BMZQ5M3","am":"8.50","iv":"","ew_strike":"","as":"2.410","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"2.350","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"0.095","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"薛群","underlying_ric":"1228.HK","hi52":"3.100","issuer_name":"北海康成製藥有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"2.350","mkt_cap":"1.17","f_aum_hkd":null,"ew_sub_per_to":"","ls":"2.350","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.170","aum":"","issued_shares_class_B":null,"vo":"3.50","secondary_listing_flag":false,"listing_date":"2021年12月10日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"北海康成製藥有限公司 - B","nm_s":"北海康成－Ｂ","sym":"1228","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"CANbridge Pharmaceuticals Inc是一家全球生物製藥公司。該公司專注於罕見病轉化療法的研究、開發和商業化。該公司擁有一個藥物組合，其中包括三種獲批藥物和八種資產的管線，針對尚未滿足需求的罕見病適應症。這些包括亨特綜合徵和其他溶酶體貯積症、陣發性睡眠性血紅蛋白尿和其他補體介導的疾病、血友病A、代謝性疾病、罕見膽汁淤積性肝病和神經肌肉疾病。其管線包括Hunterase、Livmarli、CAN106和CAN103。Hunterase是一種酶替代療法，用於治療II型粘多糖貯積症（MPS II），也稱爲亨特綜合徵。Livmarli是一種口服、吸收率極低、可逆性的迴腸膽汁酸轉運蛋白抑制劑，正在開發中，用於治療罕見的膽汁淤積性肝病，包括Alagille綜合徵和進行性家族性肝內膽汁淤積症。","op":"2.520","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>大新金融中心<br/>40樓","pc":"-6.75","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"2.520","isin":"KYG1821D1097","moneyness":""}},"qid":"1759074399887"}
